Learn how next-generation sequencing is advancing antiviral drug development and resistance monitoring.

As antiviral therapies continue to evolve, accurately detecting low-frequency viral variants is essential for evaluating therapeutic efficacy, monitoring resistance, and supporting regulatory submissions. This webinar highlights how next-generation sequencing (NGS) is being applied to identify minority variants with greater sensitivity than traditional sequencing methods.

Using a validated respiratory syncytial virus (RSV) case study, discover how deep sequencing can improve variant detection and support antiviral clinical trials.

Topics include:

• Why minority variant detection is critical for antiviral drug and vaccine development
• Advantages of NGS compared with traditional Sanger sequencing
• Development and validation of an NGS assay for RSV resistance monitoring
• FDA considerations for NGS data submissions in support of antiviral drug development
• How deep sequencing supports accurate detection of viral resistance mutations

Whether you're developing antiviral therapies or implementing sequencing-based bioanalytical methods, this webinar provides practical insights into applying NGS technologies to generate reliable data that support clinical development and regulatory decision-making.